Gamida Cell, a Phase 3 biotech developing therapies for hematologic malignancies, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
The Jerusalem , Israel-based company was founded in 1998 and plans to list on the Nasdaq under the symbol GMDA. Gamida Cell filed confidentially on June 1, 2018. BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
